Colin Minchom, PhD
Principal CMC Consultant
With extensive experience in drug development, organizations and CMC, Colin Minchom advises, project manages, and executes on CMC formulation & drug delivery strategy and development for companies at all stages in the development continuum; mitigating risk and facilitating cost & time effective development pathways.
Previously at Shire as the CMC lead for two priority programs, he was also the head of CMC Due Diligence for synthetic molecules.
Dr. Minchom worked in contract services for fourteen years including holding executive leadership positions at Patheon latterly leading development in North America and Hovione where he led the teams improving bioavailability of poorly soluble molecules. He previously worked at Eli Lilly at the discovery/development interface, and also a UK startup.
Colin Minchom is a life science mentor at MassCONNECT, the Massachusetts Biotechnology Council entrepreneur mentorship program. He was a drug development advisor at MaRS, a Toronto medical science incubator, where he lectured on drug product development best practices for startups. Dr. Minchom was active in the American Association of Pharmaceutical Scientists, having chaired the 25th anniversary AAPS annual meeting.
Colin Minchom sits on the General Chapters Expert Committee for the USP focused on Dosage Forms, lectures at Harvard Medical School, and presented at an MIT conference on enabling drug delivery technologies.
Dr. Minchom received his PhD in Industrial Pharmacy from the University of Wales, UK and is a Fellow of the Royal Pharmaceutical Society of Great Britain.